eszopiclone and Sleep-Wake-Disorders

Sleep and wake are two fundamental states of human existence. Conditions such as insomnia and hypersomnia can have profound negative effects on human health. Many pharmacological interventions impacting sleep and wake are available or are under development. This brief digest surveys early approaches to sleep modulation and highlights recent developments in sleep modulating agents.

Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agents

To investigate the effects of eszopiclone on sleep quality and cognitive function in elderly patients with Alzheimer's disease (AD) and sleep disorders.. This study was a prospective study of 96 elderly patients with AD and sleep disturbance treated in our hospital from April 2019 to December 2020. All patients were divided into a control group (48 patients, given alprazolam tablets) and a study group (48 patients, given eszopiclone) according to the random number table method.. After treatment, compared with the control group, the study group had lower sleep latency, daytime function, sleep disturbance, sleep efficiency, sleep quality, sleeping time, and hypnotic medication scores (p < .05). After treatment, sleep progression and sleep architecture improvement were more obvious in the study group compared with the control group (p < .05). After treatment, compared with the control group, the rhythm disturbance, psychotic disorder, hallucination, phobic anxiety, and disorder in the study group improved more significantly (p < .05). After treatment, compared with the control group, the scores of orientation, attention, memory, calculation, recall, and language ability in the study group improved more significantly (p < .05). After treatment, the scores of the physical life self-care scale and instrumental activities of daily living scale in the study group were improved more obviously compared with the control group, with significant differences (p < .05).. Eszopiclone can effectively improve the quality of sleep and cognitive function in elderly patients with AD and sleep disorder.

Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Double-Blind Method; Eszopiclone; Humans; Hypnotics and Sedatives; Prospective Studies; Sleep Initiation and Maintenance Disorders; Sleep Quality; Sleep Wake Disorders; Treatment Outcome

Topics: Aged; Double-Blind Method; Eszopiclone; Humans; Hypertension; Hypnotics and Sedatives; Sleep; Sleep Quality; Sleep Wake Disorders

Patients transferred out of the intensive care unit (ICU) are always impaired by sleep disorders. Cognitive behavioral therapy for insomnia (CBT-I) and eszopiclone are 2 commonly prescribed strategies for insomnia. In the current study, the effect of the combined application of the 2 methods on sleep disorders in ICU transferred out patients was assessed.Twenty-nine insomnia patients receiving combined treatment of CBT-I and eszopiclone and a corresponding number of patients treated with eszopiclone were collected. The incidence of discomfort experiences in ICU was recorded. Polysomnogram (PSG), Pittsburgh Sleep Quality Index (PSQI), self-rating anxiety scale (SAS), self-rating depression scale (SDS), and treatment emergent symptom scale (TESS) were used to assess the treatment efficacy and side effects.Hospitalization for over 7 days, use of benzodiazepines, and experiencing anxiety, insomnia, and mechanical ventilation increased chances of sleep disorders. The sleep latency, awakening time, and total sleep time were further improved in patients treated with the combined therapy than patients treated with eszopiclone (t = -2.334, -2.412, 2.383, P < .05). Similar changing pattern was observed for PSQI score (t = -2.262, P < .05). The improvement effect of the combined therapy on the sleep efficacy, SWS phase III, and rapid eye movement sleep was also significantly stronger (t = 2.112, 2.268, 2.311, P < .05). Moreover, the SAS and SDS scores in patients treated with the combined therapy decreased more than those of patients treated with eszopiclone.The efficacy of CBT-I combined with eszopiclone in the treatment of sleep disorders in ICU transferred out patients was better than eszopiclone.

Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Eszopiclone; Female; Humans; Hypnotics and Sedatives; Intensive Care Units; Male; Middle Aged; Patient Transfer; Retrospective Studies; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders; Treatment Outcome

Topics: Adverse Drug Reaction Reporting Systems; Azabicyclo Compounds; Bias; Conflict of Interest; Controlled Clinical Trials as Topic; Drug Industry; Eszopiclone; Humans; Hypnotics and Sedatives; National Institutes of Health (U.S.); Piperazines; Research Support as Topic; Restless Legs Syndrome; Sleep Wake Disorders; Treatment Outcome; United States; United States Department of Veterans Affairs; United States Food and Drug Administration